Ciaffoni Joseph 4
4 · COLLEGIUM PHARMACEUTICAL, INC · Filed Dec 20, 2023
Insider Transaction Report
Form 4
Ciaffoni Joseph
Chief Operating Officer
Transactions
- Sale
Common Stock
2023-12-19$30.03/sh−14,516$435,942→ 275,000 total - Sale
Common Stock
2023-12-20$30.40/sh−26,454$804,210→ 275,000 total - Exercise/Conversion
Common Stock
2023-12-18$21.34/sh+27,798$593,209→ 302,798 total - Exercise/Conversion
Stock Option (Right to Purchase)
2023-12-18−27,798→ 62,202 totalExercise: $21.34Exp: 2030-02-05→ Common Stock (27,798 underlying) - Exercise/Conversion
Stock Option (Right to Purchase)
2023-12-19−14,516→ 47,686 totalExercise: $21.34Exp: 2030-02-05→ Common Stock (14,516 underlying) - Exercise/Conversion
Stock Option (Right to Purchase)
2023-12-20−26,454→ 21,232 totalExercise: $21.34Exp: 2030-02-05→ Common Stock (26,454 underlying) - Exercise/Conversion
Common Stock
2023-12-20$21.34/sh+26,454$564,528→ 301,454 total - Sale
Common Stock
2023-12-18$30.04/sh−27,798$834,935→ 275,000 total - Exercise/Conversion
Common Stock
2023-12-19$21.34/sh+14,516$309,771→ 289,516 total
Footnotes (5)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2023.
- [F2]The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.145, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
- [F3]The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.185, inclusive.
- [F4]The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.00 to $30.64, inclusive.
- [F5]Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2021, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the following three-year period, subject to the Reporting Person's continued service with the Issuer.